Kathleen I Pritchard Selected Research

exemestane (Aromasin)

1/2018	Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27.
7/2017	Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.
12/2016	Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy.
4/2016	Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.
2/2016	Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
1/2015	Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
4/2014	Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
12/2013	Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
11/2013	Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.
10/2013	Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kathleen I Pritchard Research Topics

Disease

157	Breast Neoplasms (Breast Cancer) 12/2021 - 01/2002
59	Neoplasms (Cancer) 01/2022 - 01/2002
12	Neoplasm Metastasis (Metastasis) 01/2018 - 12/2003
8	Osteoporosis 12/2021 - 11/2003
8	Obesity 01/2020 - 01/2002
4	Pain (Aches) 07/2016 - 10/2006
4	Exanthema (Rash) 01/2016 - 01/2013
3	Metabolic Bone Diseases (Osteopenia) 07/2017 - 11/2008
3	Anemia 07/2017 - 03/2007
3	Arthralgia (Joint Pain) 04/2017 - 11/2003
3	Bone Fractures (Bone Fracture) 07/2016 - 09/2005
3	Fatigue 03/2016 - 02/2012
3	Triple Negative Breast Neoplasms 10/2014 - 08/2007
3	Disease Progression 05/2013 - 11/2011
3	Nausea 12/2010 - 12/2006
3	Hot Flashes 12/2010 - 11/2003
3	Vomiting 02/2010 - 12/2006
3	Insulin Resistance 04/2009 - 11/2005
2	Second Primary Neoplasms (Neoplasms, Second) 07/2018 - 05/2017
2	Myalgia 04/2017 - 11/2003
2	Hypertension (High Blood Pressure) 04/2017 - 01/2010
2	Dyspnea (Shortness of Breath) 04/2017 - 02/2012
2	Pathologic Complete Response 04/2016 - 01/2010
2	Neoplasm Micrometastasis 04/2016 - 07/2006
2	Diarrhea 05/2015 - 12/2008
2	Lymphedema (Milroy Disease) 10/2013 - 07/2008
2	Uterine Hemorrhage (Uterine Bleeding) 04/2013 - 11/2003
2	Stomatitis 02/2012 - 12/2009
2	Bone Resorption 09/2011 - 08/2006
2	Type 2 Diabetes Mellitus (MODY) 02/2011 - 12/2008
2	Constipation 12/2010 - 12/2008
2	Neutropenia 01/2010 - 12/2009
2	Amenorrhea 09/2005 - 01/2005
1	Phototoxic Dermatitis (Phototoxicity) 01/2022
1	DNA Repair-Deficiency Disorders (Chromosome Instability Syndromes) 01/2022
1	Osteoporotic Fractures 12/2021
1	Cognitive Dysfunction 10/2020
1	Dementia (Dementias) 01/2020

Drug/Important Bio-Agent (IBA)

43	Hormones (Hormone)IBA 11/2019 - 08/2002
33	Tamoxifen FDA LinkGeneric 12/2021 - 08/2002
30	Aromatase InhibitorsIBA 12/2021 - 08/2002
17	exemestane (Aromasin)FDA Link 01/2018 - 10/2005
16	Estrogen ReceptorsIBA 11/2019 - 07/2002
15	Trastuzumab (Herceptin)FDA Link 01/2021 - 10/2008
14	AnthracyclinesIBA 12/2021 - 08/2005
14	Letrozole (Femara)FDA LinkGeneric 01/2018 - 11/2003
12	Cyclophosphamide (Cytoxan)FDA LinkGeneric 05/2015 - 12/2003
11	ErbB Receptors (EGF Receptor)IBA 01/2019 - 05/2006
11	Anastrozole (Arimidex)FDA LinkGeneric 01/2018 - 08/2002
11	Progesterone Receptors (Progesterone Receptor)IBA 11/2017 - 12/2003
10	Insulin (Novolin)FDA Link 01/2020 - 01/2002
10	Fluorouracil (Carac)FDA LinkGeneric 05/2015 - 12/2003
9	Methotrexate (Mexate)FDA LinkGeneric 05/2015 - 12/2003
8	Lapatinib (GW572016)FDA Link 01/2021 - 01/2013
8	Everolimus FDA Link 02/2016 - 02/2012
7	Biomarkers (Surrogate Marker)IBA 12/2021 - 08/2009
7	Estrogens (Estrogen)FDA Link 12/2021 - 04/2002
7	Epirubicin (Ellence)FDA LinkGeneric 01/2015 - 08/2005
6	human ERBB2 proteinIBA 07/2018 - 03/2011
6	Octreotide (Sandostatin)FDA LinkGeneric 01/2016 - 09/2011
5	ParaffinIBA 12/2021 - 05/2006
5	Pharmaceutical PreparationsIBA 01/2018 - 09/2008
5	Metformin (Glucophage)FDA LinkGeneric 07/2017 - 12/2008
5	Diphosphonates (Bisphosphonates)IBA 07/2017 - 12/2003
5	Bevacizumab (Avastin)FDA Link 10/2014 - 11/2011
4	Formaldehyde (Formol)FDA Link 12/2021 - 05/2006
4	LeptinIBA 01/2020 - 09/2005
4	Fulvestrant (Faslodex)FDA Link 11/2019 - 01/2003
4	taxaneIBA 05/2015 - 05/2008
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2010 - 12/2006
3	Vitamin D FDA LinkGeneric 01/2020 - 08/2009
3	DNA (Deoxyribonucleic Acid)IBA 12/2016 - 01/2005
3	Biological ProductsIBA 10/2016 - 07/2006
3	RNA (Ribonucleic Acid)IBA 01/2016 - 01/2010
3	Docetaxel (Taxotere)FDA Link 01/2015 - 01/2010
3	Aromatase (CYP19)IBA 07/2009 - 09/2005
3	LipidsIBA 04/2009 - 11/2005
2	MA 12 (MA12)IBA 12/2021 - 08/2012
2	Progesterone FDA LinkGeneric 12/2021 - 04/2002
2	Epidermal Growth Factor (EGF)IBA 04/2016 - 08/2013
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 11/2015 - 04/2012
2	Phenobarbital (Luminal)FDA Link 05/2015 - 01/2015
2	Glucose (Dextrose)FDA LinkGeneric 03/2015 - 04/2009
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2014 - 02/2010
2	TOR Serine-Threonine KinasesIBA 08/2013 - 02/2012
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 02/2010 - 01/2010
2	Hematoxylin (Haematoxylon)IBA 01/2010 - 07/2006
2	Eosine Yellowish-(YS) (Eosin)IBA 01/2010 - 07/2006
2	tesmilifene (DPPE)IBA 01/2009 - 12/2006
2	CholesterolIBA 12/2008 - 11/2005
2	Gonadotropin-Releasing Hormone (GnRH)FDA Link 08/2007 - 01/2003
2	collagen type I trimeric cross-linked peptideIBA 10/2006 - 08/2006
2	Oncogene Proteins (Oncogene Protein)IBA 01/2006 - 01/2005
1	CX 5461IBA 01/2022
1	Inositol (Myoinositol)IBA 12/2021
1	NestinIBA 12/2021

Therapy/Procedure

85	Therapeutics 12/2021 - 08/2002
33	Drug Therapy (Chemotherapy) 12/2021 - 03/2003
22	Adjuvant Chemotherapy 10/2020 - 08/2005
4	Aftercare (After-Treatment) 11/2017 - 01/2005